- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00706550
Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects
Immune Responses to Pneumococcal Vaccination Among HIV-Infected Subjects
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- Michael E DeBakey VA Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- HIV infected
- CD4 count >200
- no acute illness
- no pneumococcal vaccination within 3 years
- naive to treatment or if previously on treatment, no antiretroviral treatment for at least 6 months
- willingness to start antiretroviral treatment as recommended by current guidelines
Exclusion Criteria:
- prior pneumococcal vaccination within 3 years
- prior AIDS diagnosis based on opportunistic disease
- acute illness
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Sonstiges: Immediate
Arm 1 will receive PV (23-valent pneumococcal polysaccharide vaccine) prior to starting antiretroviral treatment and will receive PLACEBO after at least 6 months of starting antiretroviral treatment. PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine |
Placebo
Currently commercially available pneumococcal polysaccharide vaccine
Andere Namen:
|
Sonstiges: Delayed
Arm 2 will receive PLACEBO prior to starting antiretroviral treatment and will receive PV (23-valent pneumococcal polysaccharide vaccine) after at least 6 months of starting antiretroviral treatment. PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine |
Placebo
Currently commercially available pneumococcal polysaccharide vaccine
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Immunoglobulin G (IgG) Levels
Zeitfenster: Baseline
|
Immunoglobulins are antibodies or special proteins that the immune system produces to protect the body against infections.
IgG is the most common antibody.
We measure baseline levels (before the vaccine is administered) to know how much antibody the subject has at the start point to be able to evaluate how much antibody is produced after the vaccine is administered.
|
Baseline
|
IgG Levels
Zeitfenster: One-month post-vaccine
|
Immunoglobulins are antibodies or special proteins that the immune system produces to protect the body against infections.
IgG is the most common antibody.
This point of time (one-month after vaccine), gives the information about how much antibody was produced by the participant's immune system in response to the vaccine.
|
One-month post-vaccine
|
Immunoglobulin M (IgM) Levels
Zeitfenster: Baseline
|
Immunoglobulins are antibodies or special proteins that the immune system produces to protect the body against infections.
IgM is the first antibody produced by the immune system to fight a new infection.
We measure baseline levels (before the vaccine is administered) to know how much antibody the subject has at the start point to be able to evaluate how much antibody is produced after the vaccine is administered.
|
Baseline
|
IgM Levels
Zeitfenster: One-month post-vaccine
|
Immunoglobulins are antibodies or special proteins that the immune system produces to protect the body against infections.
IgM is the first antibody produced by the immune system to fight a new infection.
This point of time (one-month after vaccine), gives the information about how much antibody was produced by the participant's immune system in response to the vaccine.
|
One-month post-vaccine
|
Opsonophagocytic Killing Activity (OPA)
Zeitfenster: Baseline
|
This assay helps us to know how the antibody produced by the body are working to kill the bacteria against which the antibody is produced.
As explained previously for the immunoglobulins' assays, we measure the baseline point to be able to determine the increase after the vaccine is administered.
|
Baseline
|
Opsonophagocytic Killing Activity (OPA)
Zeitfenster: One-month post-vaccine
|
This assay helps us to know how the antibody produced by the body are working to kill the bacteria against which the antibody is produced.
This point of time (one-month after vaccine), gives the information about how much the killing activity increased 1 month after the vaccine was administered.
|
One-month post-vaccine
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Maria Rodriguez-Barradas, MD, Michael E. DeBakey VA Medical Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- Erkrankungen des Immunsystems
- HIV-Infektionen
- Physiologische Wirkungen von Arzneimitteln
- Immunologische Faktoren
- Heptavalenter Pneumokokken-Konjugatimpfstoff
Andere Studien-ID-Nummern
- INDA-002-08S
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur HIV-Infektionen
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
University of MalayaTeleflexRekrutierungCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
Johns Hopkins UniversityAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionVereinigte Staaten
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
National Taiwan University HospitalAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
Port Said UniversityRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Ägypten
-
Boston Children's HospitalSterileCare Inc.Anmeldung auf EinladungZentrale Linienkomplikation | Central Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
Klinische Studien zur Placebo
-
SamA Pharmaceutical Co., LtdUnbekanntAkute Bronchitis | Akute Infektion der oberen AtemwegeKorea, Republik von
-
National Institute on Drug Abuse (NIDA)AbgeschlossenCannabiskonsumVereinigte Staaten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAbgeschlossenMännliche Probanden mit Typ-II-Diabetes (T2DM)Deutschland
-
Longeveron Inc.BeendetHypoplastisches LinksherzsyndromVereinigte Staaten
-
Texas A&M UniversityNutraboltAbgeschlossenGlucose and Insulin Response
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Abgeschlossen
-
Soroka University Medical CenterAbgeschlossen
-
Regado Biosciences, Inc.AbgeschlossenGesunder FreiwilligerVereinigte Staaten
-
ItalfarmacoAbgeschlossenBecker-MuskeldystrophieNiederlande, Italien